Premium
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Author(s) -
Palandri Francesca,
Palumbo Giuseppe A.,
Abruzzese Elisabetta,
Iurlo Alessandra,
Polverelli Nicola,
Elli Elena,
Bonifacio Massimiliano,
Bergamaschi Micaela,
Martino Bruno,
Tiribelli Mario,
Benevolo Giulia,
Tieghi Alessia,
Sgherza Nicola,
Isidori Alessandro,
Binotto Gianni,
Crugnola Monica,
Heidel Florian,
Cavazzini Francesco,
Bosi Costanza,
Auteri Giuseppe,
Cattaneo Daniele,
Foà Robin,
Lemoli Roberto M.,
Cuneo Antonio,
Krampera Mauro,
Bartoletti Daniela,
Cavo Michele,
Vianelli Nicola,
Breccia Massimo,
Latagliata Roberto
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2619
Subject(s) - ruxolitinib , myelofibrosis , medicine , myeloproliferative neoplasm , overall survival , oncology , pediatrics , bone marrow
The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early‐PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia‐free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment.